The funds will boost the company’s initiatives in drug research and discovery, with a focus on advancing AI-driven solutions. Peptris aims to develop new treatments for challenging targets, particularly in rare diseases, inflammation, and oncology.
Peptris, established by Narayanan Venkatasubramanian, Anand Budni, and Amit Mahajan, has created an AI/ML-based computational platform for expediting the discovery of new drugs.
This platform accelerates the drug development process by efficiently sorting through extensive datasets, significantly reducing the time required for lab testing and enabling the rapid identification and development of potential drug candidates.
Incorporating AI into drug discovery, especially in the realm of rare diseases, tackles more than 7,000 identified conditions that currently lack approved treatments.
Narayanan Venkatasubramanian, CEO and Co-founder, Peptris, said, “We are thrilled to announce that we have secured investment from Speciale Invest. We are particularly impressed by their breadth of investment in the deep tech sector, which reflects a profound understanding and commitment to driving technological advancements. This partnership marks a significant milestone in our journey. The current funding will help us accelerate our AI-powered discovery programs and create a robust pipeline of potential drug candidates.”
“The backing from Speciale Invest is set to catalyse Peptris’ journey, supporting the expansion of the drug pipeline and further refinement of the platform. This funding isn’t just an investment in technology; it’s an investment in the future of healthcare in India, bringing hope of more accessible and affordable treatments to millions,” Venkat further added.